Cory Renauer

5 days ago | fool.com | Cory Renauer

Shares of Summit Therapeutics (SMMT -30.39%) tanked more than 30% on Friday, May 30. Such dramatic price swings aren't unusual in the biotechnology industry; in this case, disappointing data from an important clinical trial drove the stock down. Stock markets have a tendency to sell first and ask questions later. After watching this stock plummet, some bargain-shoppers are wondering if it fell too far.

6 days ago | fool.com | Cory Renauer

High-yield dividend stocks are great, but you know what's even better? High-yield dividends that can grow rapidly. Prologis (PLD -0.56%), MPLX (MPLX 0.35%), and McCormick (MKC 0.21%) present investors with an unusual opportunity. They've been offering yields that are more than double the market average, plus they tend to raise their payouts rapidly. Here's why there's a good chance they'll generate a double-digit yield on cost for investors who buy now and hold over the long run. 1.

1 week ago | fool.com | Cory Renauer

Investors looking for stocks that can produce heaps of passive income are often tempted by ultra-high-yield stocks that offer yields more than triple the market average. Unfortunately, a dividend stock's yield rarely rises to such heights unless investors have good reasons to worry about future cash flows being sufficient to raise the payout further.

1 week ago | fool.com | Cory Renauer

Since its debut in 1957, the S&P 500 (^GSPC -0.67%) index has served as the gold standard for measuring investment performance. It's a collection of the largest publicly traded companies arranged according to each company's market cap. This means giants like Apple, Nvidia, and Microsoft represent an outsized percentage of the overall index. Some investors complain that the S&P 500 is too heavily weighted toward its largest components, but you can't argue with its track record.

2 weeks ago | fool.com | Cory Renauer

Have you ever wondered if an established drugmaker could do better at genetics-guided research than a consumer-focused diagnostics business? Well, we could find out. Recently, Regeneron (REGN -1.41%) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its previous market value. You might remember that the genetic testing company filed for Chapter 11 bankruptcy protections in March. Regeneron's purchase is still subject to court approval.